Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy

Nature Biotechnology

Volumn 34, Issue 4, 2016, Pages 430-434

  Liu, Lingfeng ^a   Sommermeyer, Daniel ^a   Cabanov, Alexandra ^a   Kosasih, Paula ^a   Hill, Tyler ^a   Riddell, Stanley R ^a,b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; CELL MEMBRANES; CELLS; CYTOLOGY; INDUSTRIAL RESEARCH;

ANTIGEN RECEPTORS; CGMP MANUFACTURING; CHIMERIC RECEPTORS; FUNCTIONAL ELEMENTS; OPTIMAL FUNCTION; RAPID PURIFICATION; RESEARCH APPLICATIONS; T CELL RECEPTOR;

T-CELLS;

ANTIBODY; CHIMERIC ANTIGEN RECEPTOR; CYCLIC GMP; LYMPHOCYTE ANTIGEN RECEPTOR; T LYMPHOCYTE RECEPTOR; OLIGOPEPTIDE; TRP-SER- HIS-PRO-GLN-PHE-GLU-LYS;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ENGINEERING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURIFICATION; T LYMPHOCYTE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL TRACKING; CHEMISTRY; CYTOLOGY; FEMALE; GENETIC ENGINEERING; GENETICS; METABOLISM; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; CELL TRACKING; FEMALE; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, TRANSGENIC; OLIGOPEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 84963569476     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3461     Document Type: Article

References (22)

1. Brentjens, R.J., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38 (2013).
2. Kochenderfer, J.N., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540-549 (2015).
3. Robbins, P.F., et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21, 1019-1027 (2015).
4. Morgan, R.A., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129 (2006).
5. Maude, S.L., et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507-1517 (2014).
6. Korndorfer, I.P. & Skerra, A. Improved affinity of engineered streptavidin for the Strep-tag II peptide is due to a fixed open conformation of the lid-like loop at the binding site. Protein Sci. 11, 883-893 (2002).
7. Stemberger, C., et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 124, 628-637 (2014).
8. Hudecek, M., et al. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol. Res. 3, 125-135 (2015).
9. Wang, X., et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255-1263 (2011).
10. Wang, W., Epler, J., Salazar, L.G. & Riddell, S.R. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res. 66, 6826-6833 (2006).
11. Levine, B.L., et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939-1943 (1996).
12. Kalamasz, D., et al. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J. Immunother. 27, 405-418 (2004).
13. Maude, S.L., Shpall, E.J. & Grupp, S.A. Chimeric antigen receptor T-cell therapy for ALL. ASH Education Book 2014, 559-564 (2014).
14. Hudecek, M., et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153-3164 (2013).
15. Yam, P.Y., et al. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol. Ther. 5, 479-484 (2002).
16. Kuball, J., et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 109, 2331-2338 (2007).
17. Sommermeyer, D. & Uckert, W. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J. Immunol. 184, 6223-6231 (2010).
18. Leisegang, M., et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J. Mol. Med. 86, 573-583 (2008).
19. Kieback, E., Charo, J., Sommermeyer, D., Blankenstein, T. & Uckert, W. A safeguard eliminates T cell receptor gene-modified autoreactive T cells after adoptive transfer. Proc. Natl. Acad. Sci. USA 105, 623-628 (2008).
20. Riddell, S.R. & Greenberg, P.D. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 128, 189-201 (1990).
21. Robins, H.S., et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood 114, 4099-4107 (2009).
22. Robins, H., et al. Ultra-sensitive detection of rare T cell clones. J. Immunol. Methods 375, 14-19 (2012).